Abstract C051: MDM2 inhibitor KRT-232 extends survival in glioblastoma patient-derived xenograft models
Ann C. Mladek(Mayo Clinic), Jann N. Sarkaria(Mayo Clinic in Arizona), William F. Elmquist(University of Minnesota), Danielle M. Burgenske(Mayo Clinic in Arizona), Shiv K. Gupta(Mayo Clinic), Brett L. Carlson(University of California, San Francisco), Afroz S. Mohammad(University of Minnesota), Minjee Kim(Massachusetts Eye and Ear Infirmary), Katrina K. Bakken(Mayo Clinic in Arizona), Zeng Hu(Mayo Clinic in Arizona), Helen He(Icahn School of Medicine at Mount Sinai)
Cited by 3
Related Papers
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
|Journal of Clinical Oncology|2008|275
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
|Molecular Cancer Therapeutics|2007|203
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
|Neuro-Oncology|2012|187
The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain
|Journal of Pharmacology and Experimental Therapeutics|2010|159